1 April 2009: Issuers of listed transferable securities are required to provide Oslo Børs with an annual statement of information made available to the public, cf the Securities Trading Act section 5-11 first subsection. Attached you will find an annual overview for NorDiag ASA for the period of April 1 2008 to April 1 2009.

Contact:             
CFO Tone Kvåle
telephone + 47 915 19576.

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Find the attachment here

Read the notice in Norwegian here